The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia-Reference-Cited by-同舟云学术

The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia

Published:2016-09-16 Issue:6 Volume:23 Page:1493-1505
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Matas-Céspedes Alba,Vidal-Crespo Anna,Rodriguez Vanina,Villamor Neus,Delgado Julio,Giné Eva,Roca-Ho Heleia,Menéndez Pablo,Campo Elías,López-Guillermo Armando,Colomer Dolors,Roué Gaël,Wiestner Adrian,Parren Paul W.H.I.,Doshi Parul,van Bueren Jeroen Lammerts,Pérez-Galán Patricia

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD38 regulates chronic lymphocytic leukemia proliferation via CD45 phosphatase activity;Molecular Therapy: Oncology;2024-09

2. Trastuzumab, a monoclonal anti-HER2 antibody modulates cytotoxicity against cholangiocarcinoma via multiple mechanisms;International Immunopharmacology;2024-09

3. Targeting the tumor microenvironment for treating double-refractory chronic lymphocytic leukemia;Blood;2024-08-08

4. CD38/NAD+ glycohydrolase and associated antigens in chronic lymphocytic leukaemia: From interconnected signalling pathways to therapeutic strategies;Biochimie;2024-07

5. The Value of Neutrophil Gelatinase-Associated Lipocalin Receptor as a Novel Partner of CD38 in Chronic Lymphocytic Leukemia: From an Adverse Prognostic Factor to a Potential Pharmacological Target?;Biomedicines;2023-08-22